PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8727797

The interferons.

K Skalla
View original source ↗Export metadata ↓

Abstract

OBJECTIVE: To provide a review of the biology, pharmacology, clinical application, and toxic effects of interferon and strategies for nursing management. DATA SOURCES: Research studies, review articles, and book chapters pertaining to interferons. CONCLUSIONS: Interferons are active therapeutic agents for hairy cell leukemia, chronic myelogenous leukemia, melanoma, and acquired immunodeficiency syndrome-related Kaposi's sarcoma. Clinical trials continue to investigate the clinical application of interferons. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses can facilitate patient self-care in managing side effects of interferon therapy, provide patient and family education, and assist with reimbursement concerns.

Explore related subjects

Clinical Trials as TopicInterferonsLeukemiaNeoplasmsPatient Care TeamPatient Education as TopicTreatment OutcomeJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Skalla. 1996. The interferons.. https://doi.org/10.1016/s0749-2081(96)80004-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

New antithrombotic agents.

The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory monitoring because of concerns about safety. Orally active direct inhibitors of thrombin and factor Xa may replace coumarins. Aspirin is of limited efficacy because it inhibits only one pathway of platelet activation. Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin and are used in the clinic.

Clinical Trials as Topic↗